Clene Inc. CLNN Archives

WednesdayApr 02, 2025 9:45 am

Clene Inc. (NASDAQ: CLNN) to Share CNM-Au8(R) Progress at Jones Las Vegas Conference

The company will present at the Jones Las Vegas Technology and Innovation Conference on April 8-9, to update investors on its lead drug candidate. The conference will provide one-on-one meetings and networking opportunities for institutional investors and executives. Clene recently received FDA guidance on a potential accelerated approval pathway for CNM-Au8 in ALS treatment. New analyses suggest CNM-Au8 improves survival for ALS patients, with a 4.1-month increase in restricted mean survival time. Clene plans to begin enrollment for a Phase 3 confirmatory trial (RESTORE-ALS) in mid-2025. Clene (NASDAQ: CLNN) and its wholly owned subsidiary, Clene Nanomedicine Inc., a late clinical-stage…

TuesdayApr 01, 2025 9:50 am

QualityStocksNewsBreaks – Clene Inc. (NASDAQ: CLNN) to Present at Jones Healthcare and Technology Innovation Conference on April 9

Clene (NASDAQ: CLNN), a late clinical-stage biopharmaceutical company advancing treatments for neurodegenerative diseases like ALS and MS, will present at the Jones Healthcare and Technology Innovation Conference on April 9, 2025, at 11:30 a.m. PT. The event will be held at the Venetian Resort in Las Vegas and include 1x1 investor meetings. A webcast of the presentation will be available via the events section of Clene’s website. To view the full press release, visit https://ibn.fm/16NsQ About Clene Inc. Clene (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., is a late clinical-stage biopharmaceutical company focused on improving…

ThursdayMar 27, 2025 9:45 am

Clene Inc.’s (NASDAQ: CLNN) Q1 Virtual Investor Summit Presentation Available for On-Demand Viewing

Clene’s presentation by CEO Rob Etherington and CFO Morgan Brown is now available on demand on the event’s website, covering the company’s recent achievements and immediate plans for lead drug candidate CNM-Au8®. Clene is planning to submit a New Drug Application (“NDA”) to the FDA for potential accelerated approval for CNM-Au8 for ALS in the second half of 2025. The company recently released the latest data from a cross-regimen analysis of HEALEY ALS Platform Trial, showing that CNM-Au8 significantly extends survival in patients with ALS. Clene (NASDAQ: CLNN) and its wholly owned subsidiary, Clene Nanomedicine Inc., a late clinical-stage biopharmaceutical…

TuesdayMar 25, 2025 9:30 am

QualityStocksNewsBreaks – Clene Inc. (NASDAQ: CLNN) to Present at Jones Las Vegas Technology and Innovation Conference

Clene (NASDAQ: CLNN), a clinical-stage biopharmaceutical company advancing treatments for neurodegenerative diseases such as ALS and MS, will participate in the Jones Las Vegas Technology and Innovation Conference on April 8–9, 2025. Held at The Venetian Resort, the event will feature one-on-one meetings, panels, and networking with institutional investors. Clene CEO Rob Etherington will represent the company as it continues to highlight progress across its therapeutic pipeline. The conference is hosted by JonesTrading with marketing support from B2i Digital, Inc. To view the full press release, visit https://ibn.fm/WoJcw About Clene Inc. Clene (along with its subsidiaries, “Clene”) and its wholly owned…

FridayMar 21, 2025 12:28 pm

QualityStocksNewsBreaks – Clene Inc. (NASDAQ: CLNN) Unveils Progress on CNM-Au8(R), Eyes Potential Fast-Track FDA Approval

Clene (NASDAQ: CLNN) and its wholly owned subsidiary, Clene Nanomedicine Inc., a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis (“ALS”) and multiple sclerosis (“MS”), is actively advancing its lead drug candidate, CNM-Au8®. The company presented its progress at two key investor events this month, including the Q1 Virtual Investor Summit and the 37th Annual Roth Conference. At both events, Clene’s management discussed the latest achievements with CNM-Au8, a gold nanocrystal-based oral suspension that targets mitochondrial dysfunction and promotes neuronal health. The drug has shown promising results in…

WednesdayMar 19, 2025 9:00 am

Clene Inc.’s (NASDAQ: CLNN) CNM-Au8(R) Delivers Significant Survival Benefits in New Analyses of Healey ALS Platform Trial Data

Clene's CNM-Au8® treatment was demonstrated to improve survival in ALS patients by up to 14.8 months. The findings come from a post hoc analysis of the HEALEY ALS Platform Trial, comparing CNM-Au8 to a concurrently enrolled control. Strong survival benefit was observed in patients meeting the planned criteria for Clene’s upcoming Phase 3 RESTORE-ALS trial. The company is preparing to submit a New Drug Application (“NDA”) to the FDA later this year for potential accelerated approval, and further regulatory discussions and a confirmatory Phase 3 trial are planned for mid-2025. Clene (NASDAQ: CLNN) and its wholly owned subsidiary, Clene Nanomedicine…

WednesdayMar 12, 2025 9:00 am

Clene Inc. (NASDAQ: CLNN) to Present CNM-Au8(R) Updates at 37th Annual Roth Conference

The 37th Annual Roth Conference, to be held March 16-18 in Dana Point, California, will showcase the broadest group of companies in the event’s history, with senior executives from approximately 500 companies across various industries, including business services, consumer, healthcare, insurance, sustainability and technology, media and entertainment. Clene’s management will participate in a virtual fireside chat at 9:20 a.m. PST on March 18, as well as one-on-one investor meetings during the event. During the fireside chat and in investor meetings, the company will detail recent achievements and next steps for lead drug candidate CNM-Au8 for ALS and MS. Clene Inc.…

FridayMar 07, 2025 1:29 pm

QualityStocksNewsBreaks – Clene Inc. (NASDAQ: CLNN) Collaborates to Support Potential Accelerated Pathway for ALS Treatment Candidate

Clene (NASDAQ: CLNN) and its wholly owned subsidiary, Clene Nanomedicine Inc., is partnering with APST Research GmbH to analyze neurofilament light chain (“NfL”) data in evaluating its drug candidate, CNM-Au8®, for ALS treatment. Based in Germany, APST operates one of the largest ALS biomarker repositories, which includes data from over 4,300 ALS patients. This collaboration will enable Clene to compare NfL levels in patients treated with CNM-Au8 against historical ALS controls to assess the drug’s potential in slowing disease progression. The goal is to use these findings to support FDA accelerated approval for CNM-Au8 by demonstrating its ability to reduce NfL…

ThursdayMar 06, 2025 8:55 am

QualityStocksNewsBreaks – Clene Inc. (NASDAQ: CLNN) to Participate in 37th Annual Roth Conference

Clene (NASDAQ: CLNN) a late clinical-stage biopharmaceutical company developing treatments for neurodegenerative diseases such as ALS and MS, announced its participation in the 37th Annual Roth Conference. Management will host a virtual fireside chat on March 18, 2025, at 9:20 a.m. PST and conduct one-on-one investor meetings. Interested parties are encouraged to contact their Roth representative for scheduling. To view the full press release, visit https://ibn.fm/qjx1W About Clene Inc. Clene (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., is a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative…

WednesdayMar 05, 2025 10:45 am

Clene Inc. (NASDAQ: CLNN) to Highlight Latest Achievements, Next Steps for CNM-Au8(R), at Q1 Virtual Investor Summit on March 11

The Q1 Virtual Investor Summit will focus on microcap companies that are undervalued, and aim to create connections between leading investors and microcap companies Clene’s presentation will be given by CEO Rob Etherington and CFO Morgan Brown Clene’s participation in the event comes as the company is moving closer to submitting a New Drug Application to the FDA to secure potential accelerated approval for CNM-Au8® for ALS The company recently partnered with German-based APST Research GmbH to analyze neurofilament light chain (“NfL”) data for evaluating CNM-Au8 efficacy in ALS patients. Clene Inc. (NASDAQ: CLNN) and its wholly owned subsidiary, Clene…

Site Search

Company Search

Tag: Clene Inc. CLNN